Multiple Myeloma - What is the role of MRD in MM?

The potential of MRD-adapted treatment in multiple myelomaПодробнее

Using MRD to guide treatment decisions in myelomaПодробнее

Impact of pre-transplant MRD status on disease outcomes in patients with multiple myelomaПодробнее

The emerging role of MRD in assessing response to CAR T-cell therapy and TCE in R/R multiple myelomaПодробнее

MinimuMM-seq: Genome sequencing of CTCs for minimally invasive molecular characterization of MMПодробнее

Multiple Myeloma | Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4Подробнее

MRD status by mass spectrometry with EasyM predicts outcomes following autoSCT in multiple myelomaПодробнее

MRD-guided treatment cessation in multiple myelomaПодробнее

Clinical significance of MRD status in patients with MM treated with CAR-T and T-cell engagersПодробнее

Methods used to assess MRD status in multiple myelomaПодробнее

Monitoring Multiple myeloma by Next Generation FlowПодробнее

Experience with MM MRD in our clinical laboratory: theory and practiceПодробнее

Depth of response and MRD status in ultra high-risk MM: Results of the UK optimum/MUKnine trialПодробнее

CAR T-cell Therapy in Multiple MyelomaПодробнее

Using BM and PET/CT to assess MRD status in myeloma & lymphoma patients post-CAR-T therapyПодробнее

Perspectives on the role of MRD negativity in multiple myelomaПодробнее

Current and Future Treatment of Multiple MyelomaПодробнее

New Directions in Treating Multiple Myeloma in the Era of Novel AgentsПодробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma?Подробнее